Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits

AIMS/HYPOTHESIS: Empagliflozin (EMPA), an inhibitor of the renal sodium–glucose cotransporter (SGLT) 2, reduces the risk of cardiovascular death in patients with type 2 diabetes. The underlying mechanism of this effect is unknown. Elevated cardiac cytoplasmic Na(+) ([Na(+)](c)) and Ca(2+) ([Ca(2+)](...

Descripción completa

Detalles Bibliográficos
Autores principales: Baartscheer, Antonius, Schumacher, Cees A., Wüst, Rob C. I., Fiolet, Jan W. T., Stienen, Ger J. M., Coronel, Ruben, Zuurbier, Coert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518059/
https://www.ncbi.nlm.nih.gov/pubmed/27752710
http://dx.doi.org/10.1007/s00125-016-4134-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518059/
https://www.ncbi.nlm.nih.gov/pubmed/27752710
http://dx.doi.org/10.1007/s00125-016-4134-x

Ejemplares similares